MetaVia Advances Innovative Therapies for Cardiometabolic Diseases Ahead of Investor Forum
- MetaVia Inc. is developing innovative therapies for cardiometabolic diseases, focusing on obesity and metabolic disorders.
- Key therapies include DA-1726, showing promise in weight reduction and glucose control, and vanoglipel for liver function.
- CEO Hyung Heon Kim will discuss MetaVia’s pipeline at the Life Sciences Virtual Investor Forum on March 12, 2026.
MetaVia Focuses on Innovative Therapies to Tackle Cardiometabolic Diseases
MetaVia Inc., a clinical-stage biotechnology firm based in Cambridge, Massachusetts, is at the forefront of developing groundbreaking treatments for cardiometabolic diseases. As part of its strategic initiative, Hyung Heon Kim, President and CEO of MetaVia, is set to participate in a fireside chat during the upcoming Life Sciences Virtual Investor Forum on March 12, 2026. This event provides a platform for Kim to share insights into the company’s promising pipeline, particularly its therapies targeting obesity and metabolic disorders. With a start time of 10:30 AM ET, the forum facilitates real-time interaction with investors, allowing them to engage directly concerning MetaVia's health innovations.
Central to MetaVia’s research are two cutting-edge therapies: DA-1726 and vanoglipel (DA-1241). DA-1726 is an oxyntomodulin analogue functioning as a dual agonist at the glucagon-like peptide-1 receptor (GLP1R) and the glucagon receptor (GCGR). Preliminary findings from Phase 1 trials reveal that DA-1726 could outperform existing GLP1R agonists by demonstrating significant potential for weight reduction, enhanced glucose control, and waist circumference reduction. The promising results underline MetaVia's commitment to addressing unmet medical needs in the treatment of obesity and related metabolic conditions.
The second therapy, vanoglipel (DA-1241), operates by activating the G-protein-coupled receptor 119 (GPR119) and stimulating the release of essential gut peptides, including GLP-1. Pre-clinical studies illustrate vanoglipel's efficiency in promoting better liver function, lipid metabolism, and glucose regulation. Its potential is further reinforced by encouraging positive outcomes from a Phase 2a clinical study, which confirmed its benefits in hepatic health and glucose-lowering effects. Collectively, these advancements position MetaVia as a key player in the burgeoning field of cardiometabolic therapeutics, showcasing its potential to significantly improve patient outcomes.
In anticipation of the investor forum, attendees are encouraged to pre-register to ensure an orderly participation process. Additionally, those interested in personalized discussions can reach out to MetaVia's CFO, Marshall H. Woodworth, or Michael Miller from Rx Communications Group to schedule one-on-one meetings for deeper insights into the company's progress and future direction. For more information regarding MetaVia and its innovative therapies, interested parties can visit the company’s website at www.metaviatx.com.
